科研之友
微信
新浪微博
Facebook
分享链接
摘要
Maraviroc is a CCR5 inhibitor approved in 2007 for treatment of therapy experienced adult patients infected with CCR5-tropic HIV-1 virus. International guidelines for HIV therapy indicate a plasma concentration cutoff of maraviroc for response. We developed and validated a new HPLC-MS method to quantify maraviroc concentrations in human plasma. 6,7-Dimethy1-2,3-di(2-pyridyl)quinoxaline was used as internal standard and added to 100 mu L. of plasma. Samples were then treated with 500 mu L of acetonitrile for the protein precipitation procedure. An analytical T3 Atlantis column (150 mm x 4.6 mm i.d.) with a particle size of 5 was used to separate the compounds and ions were detected at m/z 257.5 and 313.3 for maraviroc and quinoxaline respectively. The calibration curve was linear up to 2500 ng/mL. The mean recovery of maraviroc was 89.1%. All validation data results were in accordance to Food and Drug Administration and European Medicines Agency requirements. The HPLC-MS method reported here could be used routinely to monitor plasma concentrations of maraviroc in HIV-infected patients.
- 出版日期2014-6
